NCT06658899

A Phase 2 Study of CRD-4730 in CPVT

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 12 (estimated)
• Sponsor: Cardurion Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, multicenter, double-blind, sponsor blinded, placebo-controlled, repeat-dose clinical study of CRD-4730 to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CRD-4730 to participants with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). Participants with CPVT will complete a 3-period, randomized 3-sequence study. Each participant will be randomized to one of the 3 sequences in which they will receive 2 different doses of CRD-4730 and 1 dose of matching placebo.

Conditions

• Catecholaminergic Polymorphic Ventricular Tachycardia

Interventions

Type	Name	Description
DRUG	CRD-4730	Oral CRD-4730 in tablet form
DRUG	Placebo	Placebo to match CRD-4730 in tablet form

Timeline

• Start date: 2025-12-01
• Primary completion: 2027-04-01
• Completion: 2027-04-01
• First posted: 2024-10-26
• Last updated: 2026-02-27

Locations

9 sites across 6 countries: United States, Canada, France, Italy, Netherlands, Spain

Regulatory

• FDA-regulated drug study